Finviz vs TradingView (2026)
Finviz is a US stock screener with a free version and one paid plan (Elite, $299.50 a year); TradingView is a charting platform covering global markets, with paid plans from $12.95 a month billed yearly. Screen with Finviz, chart with TradingView; many traders use both.
By Wealthy Pot Editorial · Facts checked October 19, 2026
| Feature | Finviz | TradingView |
|---|---|---|
| Type | Screener | Charting |
| Price | Free (delayed data); Elite $39.50/mo or $299.50/yr | Free (ads); billed yearly: Essential $12.95/mo, Plus $29.95/mo, Premium $59.95/mo, Ultimate $199.95/mo; billed monthly: $14.95, $34.95, $69.95, $239.95 |
| Cheapest paid plan, 1 year | $299.50 | $155.40 |
| Free tier | Free: delayed quotes, basic filters | Free: ads, 1 chart, 2 indicators |
| Platforms | Web | Web, iOS, Android, Desktop |
| Data coverage | US stocks and ETFs (NYSE, Nasdaq, AMEX), plus futures, forex and crypto quotes | Global equities, forex, crypto, futures, indices |
| Best for | Screening US stocks for free, plus the market heatmap | Investors and traders who decide from price charts and technical indicators |
Cost row is our arithmetic from each tool's listed prices (annual plan where one exists), before tax, assuming today's prices hold.
Key differences
Finviz covers US stocks and ETFs on NYSE, Nasdaq and AMEX. The free version delays stock quotes and keeps a basic screener; Elite ($39.50 a month or $299.50 a year) adds real-time data, interactive charts, alerts and export. Finviz ended its backtesting feature in March 2026. TradingView covers global stocks, forex, crypto and futures, and its free plan allows 1 chart per tab, 2 indicators per chart and 3 price alerts, with ads.
Real-time data is priced differently. It is included in Finviz Elite. On TradingView, real-time NYSE and Nasdaq data is a $9.95 monthly add-on that needs a paid plan. A hypothetical year: Finviz Elite costs $299.50; TradingView Essential billed yearly ($12.95 x 12 = $155.40) plus real-time US data ($9.95 x 12 = $119.40) costs $274.80.
TradingView bills monthly or yearly ($14.95 to $239.95 a month on monthly billing) and refunds annual plans within 14 days. Finviz asks for a card for its 7-day Elite trial and refunds on written request in the first 30 days.
Where Finviz wins
- Free screener and market heatmap with a registered account
- Real-time quotes, pre-market and after-hours included in Elite with no data add-on
- Elite costs $24.96 a month on yearly billing
- Export to Excel or CSV and API access on Elite
Where TradingView wins
- Real-time US stock charts from Cboe on every plan, including the free one
- Pine Script lets you write, share and backtest your own indicators and strategies
- Same layouts and alerts across web, desktop and phone apps
- Yearly billing saves $24 to $480 a year depending on the plan
Which should you choose?
Pick Finviz if
- You screen US stocks by valuation, dividends or price action and want results in seconds.
- You want a free, one-glance view of the market through the heatmap.
- You want real-time US quotes and alerts for under $300 a year.
Pick TradingView if
- You make decisions from price charts and technical indicators and want them on the web, desktop and phone.
- You want to write or reuse trading strategies in Pine Script and backtest them.
- You want free real-time US stock charts and can live with ads and 2 indicators.
Finviz vs TradingView: FAQ
Is Finviz or TradingView better for screening stocks?
Finviz is built around its US stock screener and heatmap. TradingView also has screeners but is built around charts and covers global markets.
Which is cheaper for real-time US data?
In our hypothetical year, TradingView Essential plus its real-time US data add-on ($274.80) costs a little less than Finviz Elite ($299.50), which includes real-time data. Prices as listed on October 19, 2026.
Compare these against every option in our stock analysis tools comparison.
We summarize each tool's published pricing and features, not user reviews, and we do not score tools with stars. Facts come from our full reviews of both tools, each checked against the company's own pages on October 19, 2026 with every source listed. Nothing here is investment advice.